Adoptive cell therapy for acute myeloid leukemia.

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Acute myeloid leukemia (AML) is a prevalent adult cancer with a generally poor prognosis, particularly in relapsed, refractory, or elderly patients.
• Current high-intensity chemotherapy regimens often fail to achieve durable remission in these challenging AML patient groups.
• Novel therapeutic strategies are urgently required to improve outcomes for AML patients.

Purpose of the Study:

• To review the clinical applications and advancements of adoptive cell therapy (ACT) in treating acute myeloid leukemia (AML).
• To provide an overview of the current clinical landscape and progress in various ACT modalities for AML.
• To highlight promising immunotherapeutic approaches for AML management.

Main Methods:

• Review of clinical literature on adoptive cell therapy for AML.
• Analysis of advancements in donor lymphocyte infusion (DLI) for AML.
• Evaluation of chimeric-antigen receptor (CAR) T-cell therapy in AML clinical settings.
• Assessment of natural killer (NK) cell therapy and dendritic cell (DC) vaccination strategies for AML.

Main Results:

• Adoptive cell therapy, including DLI, CAR T-cell therapy, NK cell therapy, and DC vaccination, is emerging as a promising strategy for AML.
• These immunotherapies show potential in overcoming the limitations of conventional chemotherapy, especially for difficult-to-treat AML cases.
• Ongoing research and clinical trials are expanding the application and efficacy of ACT in AML.

Conclusions:

• Adoptive cell therapy represents a significant advancement in the treatment of acute myeloid leukemia.
• Various ACT modalities offer new hope and improved therapeutic options for AML patients, including those with relapsed or refractory disease.
• Further research and clinical development of ACT are crucial for optimizing AML treatment outcomes.